65,437 trials
Congenital Heart Disease
Primary: IkB-alpha Expression — 4.1; 3.6 units on a scale
Human Papillomavirus Infection
Primary: Incidence Rate of Syncope — 24.21; 13.84 Rate per 1000 person years
Metastatic Breast Cancer · Locally Advanced Breast Cancer
Primary: Progression Free Survival (PFS) Time — 4.80 months
Chronic Kidney Disease · End Stage Renal Disease
Primary: Change in IGF-1 After 30 Days of Intervention Compared to Baseline Level. — 92.7; 6.7 ng/ml — p=<0.001
Acute Lung Injury · Sepsis · Infections
Primary: Acute Lung Injury After Cardiac Surgery — 20 participants — p=<0.05
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
Anesthesia, General
Primary: Anesthesiologist Satisfaction With the Anesthesia Recorded at the End of the Operation Using a Numeric Analog Scale (NAS) — 8.85 units on a scale
Intrapartum Fetal Monitoring · Pregnancy
Primary: Feasibility Defined as the Number of Eligible Women Who Are Successfully Monitored Remotely With Trans-abdominal Fetal Electrocardiogram (ECG) Monitoring Device (Monica…
Open-Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year — 20.8; 20.3; 20.6; -4.8 Millimeters of mercury (mmHg)
Advanced Prostate Cancer · Lower Urinary Tract Symptoms
Primary: The Change in the International Prostate Symptom Score (IPSS) From Baseline to Month 12. The IPSS Has a Range From 0 to 35. — 17.8; 10.0 units on a scale
Anemia
Primary: Change From Baseline in Hemoglobin Concentration to the Last Month of Study Participation — -0.55; -0.38 g/dL
Type 2 Diabetes Mellitus
Primary: Absolute Change From Baseline in HbA1c at Week 24 — -0.47; -0.38 Percent (%) — p=0.26
Hypotrichosis
Primary: Percentage of Treatment Responders in Overall Eyelash Prominence at Month 4 — 69.6; 48.8 Percentage of Patients
Alcohol-Related Disorders · Alcohol Dependence · Alcoholism
Primary: Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 — 1.256772; 1.294178 Ratio of glutamate to creatine
Pompe Disease (Late-Onset) · Glycogen Storage Disease Type II (GSD-II) · Glycogenesis Type II
Primary: Summary of Participants Reporting Treatment-Emergent Adverse Events For Participants Treated With Alglucosidase Alfa During Study AGLU02704 (NCT00158600) — 60; 37; 21…